Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Purified exosome product - RION

Next Previous
Drug Profile

Purified exosome product - RION

Alternative Names: 10% PEP; 20% PEP; PEP; PEPTM; Purified Exosome ProductTM

Latest Information Update: 22 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mayo Foundation for Medical Education and Research
  • Developer Mayo Foundation for Medical Education and Research; RION
  • Class Blood products and substitutes; Exosome therapies
  • Mechanism of Action Angiogenesis inducing agents; Exosome replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Diabetic foot ulcer
  • Phase I Osteoarthritis
  • Preclinical Alopecia; Joint disorders; Urinary incontinence
  • No development reported Myocardial infarction; Wounds
  • Discontinued Crohn's disease

Most Recent Events

  • 13 Jan 2025 RION completes enrolment in its phase II trial for Diabetic foot ulcer (Parenteral) in USA
  • 28 Dec 2024 No recent reports of development identified for phase-I development in Myocardial-infarction in USA (Intracoronary, Infusion)
  • 10 Sep 2024 Phase-I clinical trials in Osteoarthritis in USA (Intra-articular)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top